Have a feature idea you'd love to see implemented?
Let us know!
HRMY Harmony Biosciences Holdings Inc
Price (delayed)
$33.23
Market cap
$1.9B
P/E Ratio
15.46
Dividend/share
N/A
EPS
$2.15
Enterprise value
$1.69B
Harmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves
Highlights
The company's revenue rose by 26% YoY and by 3.9% QoQ
Harmony Biosciences Holdings's equity has increased by 24% YoY and by 11% from the previous quarter
The quick ratio has contracted by 22% YoY but it has grown by 4.1% from the previous quarter
Harmony Biosciences Holdings's net income has decreased by 19% YoY but it has increased by 7% from the previous quarter
The gross margin has contracted by 2.4% YoY
Key stats
What are the main financial stats of HRMY
Market
Valuations
Earnings
Shares outstanding
57.03M
Market cap
$1.9B
Enterprise value
$1.69B
Price to earnings (P/E)
15.46
Price to book (P/B)
3.16
Price to sales (P/S)
2.77
EV/EBIT
8.29
EV/EBITDA
7.4
EV/Sales
2.48
Revenue
$681.88M
EBIT
$204.06M
EBITDA
$228.32M
Free cash flow
$220.18M
Per share
Balance sheet
Liquidity
EPS
$2.15
Free cash flow per share
$3.87
Book value per share
$10.5
Revenue per share
$11.99
TBVPS
$14.22
Total assets
$928.14M
Total liabilities
$331.33M
Debt
$182.85M
Equity
$596.8M
Working capital
$361.13M
Debt to equity
0.31
Current ratio
3.24
Quick ratio
3.05
Net debt/EBITDA
-0.9
Margins
Efficiency
Dividend
EBITDA margin
33.5%
Gross margin
78.7%
Net margin
18%
Operating margin
25.7%
Return on assets
14.2%
Return on equity
23.2%
Return on invested capital
47.7%
Return on capital employed
26.6%
Return on sales
29.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HRMY stock price
How has the Harmony Biosciences Holdings stock price performed over time
Intraday
1.34%
1 week
0.7%
1 month
-4.92%
1 year
20.97%
YTD
2.88%
QTD
-16.93%
Financial performance
How have Harmony Biosciences Holdings's revenue and profit performed over time
Revenue
$681.88M
Gross profit
$536.32M
Operating income
$175.3M
Net income
$122.63M
Gross margin
78.7%
Net margin
18%
The net margin has contracted by 35% YoY but it has grown by 2.9% from the previous quarter
The operating margin has declined by 30% year-on-year and by 5% since the previous quarter
The company's revenue rose by 26% YoY and by 3.9% QoQ
The gross profit has grown by 23% YoY and by 2.9% from the previous quarter
Growth
What is Harmony Biosciences Holdings's growth rate over time
Valuation
What is Harmony Biosciences Holdings stock price valuation
P/E
15.46
P/B
3.16
P/S
2.77
EV/EBIT
8.29
EV/EBITDA
7.4
EV/Sales
2.48
Harmony Biosciences Holdings's EPS has decreased by 15% YoY but it has increased by 9% QoQ
The stock's price to earnings (P/E) is 2.2% less than its last 4 quarters average of 15.8
The stock's price to book (P/B) is 68% less than its 5-year quarterly average of 10.0 and 15% less than its last 4 quarters average of 3.7
Harmony Biosciences Holdings's equity has increased by 24% YoY and by 11% from the previous quarter
HRMY's P/S is 54% below its 5-year quarterly average of 6.0 and 11% below its last 4 quarters average of 3.1
The company's revenue rose by 26% YoY and by 3.9% QoQ
Efficiency
How efficient is Harmony Biosciences Holdings business performance
HRMY's return on assets is down by 31% year-on-year
The ROE is down by 30% YoY
Harmony Biosciences Holdings's return on sales has decreased by 20% YoY
HRMY's return on invested capital is down by 9% year-on-year
Dividends
What is HRMY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HRMY.
Financial health
How did Harmony Biosciences Holdings financials performed over time
HRMY's total assets is 180% greater than its total liabilities
The quick ratio has contracted by 22% YoY but it has grown by 4.1% from the previous quarter
The current ratio has contracted by 21% YoY but it has grown by 3.5% from the previous quarter
The debt is 69% less than the equity
Harmony Biosciences Holdings's equity has increased by 24% YoY and by 11% from the previous quarter
The debt to equity has declined by 24% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.